PDCD1 and neoplasm: Within tumour types, high mutational load has been demonstrated to correlate with clinical benefit to PD-1 and CTLA-4 inhibitors in NSCLC and melanoma, respectively (Snyder et al, 2014; Rizvi et al, 2015).